透景生命收盘下跌1.64%，滚动市盈率56.96倍，总市值22.50亿元

Company Overview - The company, Shanghai TuoJing Life Technology Co., Ltd., specializes in the research, production, and sales of in vitro diagnostic products under its own brand [1] - The main products include in vitro diagnostic reagents, instruments, and service revenue [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for social responsibility, including the "Social Public Welfare Award" from the China Cancer Foundation [1] Financial Performance - For Q1 2025, the company reported operating revenue of 74.89 million yuan, a year-on-year decrease of 19.53% [1] - The net profit for the same period was 471,700 yuan, showing a year-on-year increase of 110.51% [1] - The gross profit margin was reported at 63.66% [1] Market Position - As of May 22, the company's stock closed at 13.8 yuan, down 1.64%, with a rolling price-to-earnings (PE) ratio of 56.96 times [1] - The total market capitalization is 2.25 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 48.71 times, with a median of 35.37 times, placing the company at the 93rd position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 17,040, a decrease of 590 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]